Sistema renina-angiotensina disfunzionale nello shock settico (MANTRA)
Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This study will determine whether normalization of renin-angiotensin-aldosterone system (RAAS) signaling in sepsis occurs more rapidly with treatment with Angiotensin II compared with conventional vasopressors. Trial samples will be used to identify the best RAAS biomarker predictor of treatment response via in-depth longitudinal analysis of RAAS component and to determine the extent and mechanisms of Angiotensin II impact on innate immune function during sepsis. Successful accomplishment of our aims will provide the capability to improve endotyping of septic patients by establishing the most precise and robust measurement of renin (and RAAS dysfunction). This work will improve staging and clinical precision and will facilitate the criteria for therapeutic development of targets in septic shock.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 4
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Ashish Khanna, MD
- Numero di telefono: 513-658-5866
- Email: ashish.khanna@wfusm.edu
Backup dei contatti dello studio
- Nome: Lynnette Harris, RN
- Numero di telefono: 336-716-8791
- Email: lynnette.harris@advocatehealth.org
Luoghi di studio
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital-Harvard
-
Contatto:
- Michael R Filbin, MD, MS
- Email: mfilbin@mgh.harvard.edu
-
Contatto:
- Daniel E Leisman, MD
- Email: dleisman@mgh.harvard.edu
-
Investigatore principale:
- Michael R Filbin, MD, MS
-
Investigatore principale:
- Daniel E Leisman, MD
-
Sub-investigatore:
- Marcia Goldberg, MD
-
Sub-investigatore:
- Kathryn Hibbert, MD
-
-
North Carolina
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Atrium Health Wake Forest Baptist
-
Contatto:
- Lynnette C Harris, BSN
- Numero di telefono: 336-716-8791
- Email: lcharris@wakehealth.edu
-
Contatto:
- Ashish Khanna, MD
- Numero di telefono: 513-658-5866
- Email: akhanna@wakehealth.edu
-
Investigatore principale:
- Ashish Khanna, MD
-
Sub-investigatore:
- Christopher Schaich, PhD
-
Sub-investigatore:
- Daniel C Files, MD
-
Investigatore principale:
- Mark Chappell, PhD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- The presence of septic shock, defined by sepsis-3 criteria: 1-adult patients (18 years or older) with septic shock, defined by SEPSIS-3 criteria: a) suspected or known infection, b) hypotension requiring vasopressors, and c) lactate >2mmol/L 2-receiving either norepinephrine or phenylephrine with or without additional vasopressor support 3- total norepinephrine equivalent dose (NED) ≥0.1 mcg/kg/min and ≤0.5 mcg/kg/min, to maintain a MAP of at least 65 mmHg, is required for randomization 4-ability to consent and randomize within 24 hrs of first reaching NED threshold and within 48 hrs of hospital arrival
Exclusion Criteria:
- Age <18 years
- Prisoners
- Pregnant women
- Patients for whom urgent surgery is anticipated
- Leukocyte count <1,000 cells/μL
- Absolute monocyte count <200 cells/μL
- Bone marrow transplant within the past 30 days
- Patients that will be withdrawing aggressive resuscitation, including withdraw of vasopressor support
- transfer from outside ICU
- history of liver cirrhosis with Child-Pugh score ≥6
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Angiotensin II
Continuous infusion of Angiotensin II for up to 48 hours |
randomized to receive Angiotensin II continuous infusion for up to 48 hours |
|
Comparatore attivo: Norepinephrine
Continuous infusion of Norepinephrine for up to 48 hours |
randomized to receive Norepinephrine continuous infusion for up to 48 hours |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mean Renin Level - Hour 24
Lasso di tempo: Hour 24
|
Mean plasma renin level (PRA) as a measure of renin-angiotensin-aldosterone system restoration. Normal levels of active renin <1.1 pM (40 pg/mL). A level higher than normal can indicate level of shock. |
Hour 24
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Norepinephrine Equivalent Dose Requirement (NEE)
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
NEE indicates severity of shock and need for vasopressors to support blood pressure. Normal range is 0.0-1.0 mcg/kg/min. Levels above normal indicate shock and need for vasopressors. The higher the level the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
|
Number of Days Without Renal Replacement Therapy
Lasso di tempo: Day 28
|
Number of days without renal replacement therapy |
Day 28
|
|
Number of Days of Vasopressor Use
Lasso di tempo: Day 28
|
Number of days without vasopressor use |
Day 28
|
|
Number of Days Without Mechanical Ventilation
Lasso di tempo: Day 28
|
Number of days without invasive mechanical ventilation |
Day 28
|
|
Number of Hours Vasopressor Free
Lasso di tempo: Hour 72
|
Number of hours without requiring vasopressors during first 72 hours after randomization |
Hour 72
|
|
Number of Hours Alive
Lasso di tempo: Hour 72
|
Number of hours alive during first 72 hours after randomization |
Hour 72
|
|
Number of Days Alive
Lasso di tempo: Day 28
|
Number of days alive |
Day 28
|
|
Mean Renin Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 48, Hour 72
|
Mean renin level as a measure of renin-angiotensin-aldosterone system restoration. Normal levels of active renin <1.1 pM (40 pg/mL). A level higher than normal can indicate level of shock. |
Baseline, Hour 3, Hour 12, Hour 48, Hour 72
|
|
Sequential Organ Failure Assessment (SOFA) Score
Lasso di tempo: Baseline, Hour 24, Hour 48
|
SOFA score indicates the number and severity of failed organs and provides prognostic information on in-hospital survival in patients with severe sepsis and septic shock. Score above 0 indicates organ failure. The higher the score the more failed organs and degree of organ failure. |
Baseline, Hour 24, Hour 48
|
|
APACHE-II Score
Lasso di tempo: Baseline, Hour 24, Hour 48
|
APACHE-II score assesses severity of illness in critically ill patients and indicates risk of mortality. Score range 0-10 low risk of mortality, 11-20 moderate risk, 21-30 high risk, 31 or above very high risk. |
Baseline, Hour 24, Hour 48
|
|
Lactate Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
Lactate is an indicator of sepsis severity. Levels 2.3-20 mmol/L indicate sepsis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
|
Kidney Disease Improving Global Outcomes (KDIGO) Stage
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Participant stage of acute kidney injury will be determined as follows Stage 1: Increase in serum creatinine ≥ 0.3 mg/dL in 48 hours or 1.5 to 1.9 multiplied by baseline (in 7 days); Stage 2: 2.0 to 2.9 multiplied by baseline serum creatinine; Stage 3: 3.0 or more multiplied by baseline; increase in serum creatinine ≥ 4.0 mg/dL; or beginning of renal replacement therapy regardless of a previous KDIGO stage. Higher stage indicates higher severity of renal failure. |
Baseline, Hour 24, Hour 48
|
|
Creatinine Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Creatinine level is an indicator of renal disease severity. Normal range for women 0.7-1.3 mg/dL, men 0.6-1.1 mg/dL. Levels higher than normal indicate renal disease. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
BUN Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
BUN level is an indicator of renal disease severity. Levels above 24 mg/dL indicate renal disease. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Bicarbonate Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Bicarbonate level is an indicator of acid base disturbance severity. Normal range is 22-29 mEq/L. Levels above or below the normal range indicate acid base disturbance. The higher the score the more severe. |
Baseline, Hour 24, Hour 48
|
|
Number of Participants with Acute Respiratory Distress Syndrome (ARDS)
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Number of participants with ARDS |
Baseline, Hour 24, Hour 48
|
|
SpO2/FiO2 Ratio Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
SpO2/FiO2 ratio level is an indicator of lung injury severity. Mild severity 315-235, moderate severity 148-235, severe <148. |
Baseline, Hour 24, Hour 48
|
|
PaO2/FiO2 Ratio Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
PaO2/FiO2 ratio level is an indicator of lung injury severity. Mild severity 201-300 mmHg; moderate severity 101-200 mmHg, severe ≤ 100 mmHg. |
Baseline, Hour 24, Hour 48
|
|
Serum Aspartate Aminotransferases Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Serum aspartate aminotransferases level is an indicator of liver injury severity. Normal range 8-48 U/L. Levels above normal indicate livery injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Alanine Aminotransferases Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Alanine aminotransferases level is indicator of liver injury severity. Normal range 7-55 U/L. Levels higher than normal indicate liver injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Alkaline Phosphatase Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Alkaline phosphatase level is an indicator of liver injury severity. Normal range 40-129 U/L. Levels higher than normal indicate liver injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Bilirubin Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Bilirubin level is an indicator of liver injury severity. Normal range 0.1-1.2 mg/dL. Levels higher than normal indicate liver injury. The higher the liver the more severe. |
Baseline, Hour 24, Hour 48
|
|
Albumin Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Albumin level is an indicator of liver injury severity. Normal range 3.5-5.0 g/dL. Levels higher than normal indicate liver injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Troponin I Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Troponin I level is an indicator of cardiac myocyte injury. Normal range 0-0.04 ng/mL. Levels higher than normal indicate cardiac myocyte injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Troponin T Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Troponin T level is an indicator of cardiac myocyte injury. Normal range 0-0.01 ng/mL. Levels higher than normal indicate cardiac myocyte injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Neutrophil Gelatinase-Associated Lipocalin Serum Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Neutrophil gelatinase-associated lipocalin serum level indicates risk of kidney injury. Normal serum level is <10 mcg/L. Levels higher than normal indicate risk of kidney injury. |
Baseline, Hour 24, Hour 48
|
|
Neutrophil Gelatinase-Associated Lipocalin Urine Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Neutrophil gelatinase-associated lipocalin urine level indicates risk of kidney injury. Normal urine level is ≤50 ng/ml. Risk of kidney disease: Low risk 51-149 ng/ml, moderate risk 150-299 ng/ml, and high risk ≥300 ng/ml. |
Baseline, Hour 24, Hour 48
|
|
Kidney Injury Molecule-I Urine Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Kidney injury molecule-I urine level is used to detect kidney injury. Normal level is <1 ng/ml. Levels higher than normal indicate ischemic kidney injury. |
Baseline, Hour 24, Hour 48
|
|
Kidney Injury Molecule-I Blood Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Kidney injury molecule-I blood level is used to detect kidney injury. Normal levels 0.42-2.0 ng/ml. Levels higher than normal indicate kidney injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Soluble Receptor for Advanced Glycation End Product Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Soluble receptor for advanced glycation end product level is a marker of aging, hypertension and diabetes. Normal range is 647-1248 pg/ml. Levels higher than normal indicate risk for hypertension and diabetes. |
Baseline, Hour 24, Hour 48
|
|
Angiopoietin-2 Level
Lasso di tempo: Baseline, Hour 24, Hour 48, Hour 72
|
Angiopoietin-2 level is a marker of inflammation. Normal range is 1434-4141 pg/mL. Levels higher than normal indicate inflammation. |
Baseline, Hour 24, Hour 48, Hour 72
|
|
Syndecan-1 Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Syndecan-1 level is a marker of disease severity in critically ill patients. Levels >20ng/ml indicate severe disease. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Protein C Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Protein C level is an indicator of inflammation and thrombotic state. Normal level is <8 mg/L. Levels higher than normal indicate inflammation and thrombotic state. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Neuron-Specific Enolase Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
Neuron-specific enolase level is an indicator of brain injury. Normal range is 16-17 ug/L. Levels higher than normal indicate brain injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
S-100β Level
Lasso di tempo: Baseline, Hour 24, Hour 48
|
S-100β level is indicator of brain injury. Normal range is 0.02-0.05 μg/dL. Levels higher than normal indicate brain injury. The higher the number the more severe. |
Baseline, Hour 24, Hour 48
|
|
TNFα Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
TNFα level is an indicator of systemic inflammation. Normal levels are 75 +/- 15 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
sTNFR1 Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
sTNFR1 level is an indicator of systemic inflammation. Normal levels are <2.4 ng/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-6 Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-6 level is an indicator of systemic inflammation. Normal range is 0-43.5 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
sIL-6R Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
sIL-6R level is an indicator of systemic inflammation. Normal range is 14-46 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-8 Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-8 level is an indicator of systemic inflammation. Normal range is 0-66.1 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-1β Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-1β level is an indicator of systemic inflammation. Normal range is 0.5-12 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Interferon Gamma Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IFN-ɣ level is an indicator of systemic inflammation. Normal range is 0-8.6 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL12p70 Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL12p70 level is an indicator of systemic inflammation. Normal range is 0-1.9 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-17 Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-17 level is an indicator of systemic inflammation. Normal range is 0-1.4 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
MIP1-alpha Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
MIP1-αlpha level is an indicator of systemic inflammation. Normal range is 0-208 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
MIP1-beta Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
MIP1-beta level is an indicator of systemic inflammation. Normal range is 59-647 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IP-10 Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IP-10 level is an indicator of systemic inflammation. Normal range is 4.8-9.8 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-10 Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-10 level is an indicator of systemic inflammation. Normal range is 4.8-9.8 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-1RA Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-1RA level is an indicator of systemic inflammation. Normal range is 100-300 ng/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-12p40 Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-12p40 level is an indicator of systemic inflammation. Normal range is 0.064-1000 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
C reactive protein (CRP) Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
CRP level is an indicator of systemic inflammation. Normal range is 0-10 mg/dl. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Procalcitonin Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Procalcitonin level is an indicator of systemic inflammation. Levels >0.25 mg/ml indicate inflammation and infection. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Platelet Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Platelet level is an indicator of systemic inflammation and thrombocytosis. Normal range is 150000-450000 platelets per microliter. Levels higher than normal indicate inflammation and thrombocytosis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Absolute Neutrophil Count Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Absolute neutrophil count level is an indicator of inflammation and infection/sepsis. Normal range is 2500-7000 neutrophils per microliter. Levels higher than normal indicate inflammation, infection/sepsis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Absolute Granulocyte Count Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Absolute granulocyte count level is an indicator of inflammation and infection/sepsis. Normal range is 1500-8500 granulocytes per microliter. Levels higher than normal indicate inflammation, infection/sepsis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Absolute Lymphocytes Count Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Absolute lymphocyte count level is an indicator of inflammation and infection/sepsis. Normal range is 1000-4800 granulocytes per microliter. Levels higher than normal indicate inflammation, infection/sepsis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Neutrophil-Lymphocyte Ratio Level
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Neutrophil-lymphocyte ratio level is an indicator of inflammation and infection/sepsis or marrow malignancy. Normal range is 1-2. Levels higher than normal indicate inflammation, infection/sepsis, marrow malignancy. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Angiotensin (1-7)
Lasso di tempo: Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
Angiotensin (1-7) level as a measure of the renin-angiotensin-aldosterone system |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
|
Plasma renin activity
Lasso di tempo: baseline, hour 3, hour 12, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 3, hour 12, hour 24, hour 48
|
|
Prorenin
Lasso di tempo: baseline, hour 3, hour 12, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 3, hour 12, hour 24, hour 48
|
|
Soluble prorenin receptor (sPRR)
Lasso di tempo: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
Aldosterone
Lasso di tempo: baseline, hour 3, hour 12, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 3, hour 12, hour 24, hour 48
|
|
Intact Aogen
Lasso di tempo: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
ANG II
Lasso di tempo: baseline, hour 3, hour 12, hour 24, hour 48, hour 72
|
levels at indicated timepoints |
baseline, hour 3, hour 12, hour 24, hour 48, hour 72
|
|
Angiotensin-converting enzyme (ACE)
Lasso di tempo: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
Angiotensin-converting enzyme-2 (ACE2)
Lasso di tempo: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
Dipeptidyl peptidase 3 (DPP3)
Lasso di tempo: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
RNA Paxgene Bulk (Bulk RNA sequencing)
Lasso di tempo: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
Whole blood cryopreserved (scRNAsesq)
Lasso di tempo: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Patients with New Deep Venous Thrombosis
Lasso di tempo: Day 7, Day 28
|
Number of patients with development of new deep venous thrombosis |
Day 7, Day 28
|
|
Patients with New Pulmonary Embolism
Lasso di tempo: Day 7, Day 28
|
Number of patients with development of new pulmonary embolism |
Day 7, Day 28
|
|
Patients with New-Onset Atrial Fibrillation
Lasso di tempo: Hour 72, day 28
|
Number of patients with new-onset atrial fibrillation |
Hour 72, day 28
|
|
Patients with New-Onset Ventricular Arrhythmias
Lasso di tempo: Hour 72, Day 7, Day 28
|
Number of patients with new-onset ventricular arrhythmias |
Hour 72, Day 7, Day 28
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Ashish Khanna, MD, Atrium Health Wake Forest Baptist
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Processi patologici
- Malattie urogenitali maschili
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Infezioni
- Sindrome da risposta infiammatoria sistemica
- Infiammazione
- Shock
- Condizioni patologiche, segni e sintomi
- Sepsi
- Malattie renali
- Shock, settico
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Ormoni peptidici
- Neuropeptidi
- Peptidi
- Aminoacidi, peptidi e proteine
- Oligopeptidi
- Proteine del tessuto nervoso
- Proteine
- Prodotti chimici organici
- Idrocarburi
- Idrocarburi, ciclici
- Fattori biologici
- Idrocarburi, aromatici
- Ammine
- Cateco
- Fenoli
- Derivati di benzene
- Alcoli
- Aminouli
- Etanolamine
- Autacoidi
- Mediatori di infiammazione
- Monoamine biogeniche
- Amine biogeniche
- Catecolamine
- Angiotensine
- Noradrenalina
- Angiotensina II
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- IRB00115287
- R01HL177834 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .